# Extended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia

> **NCT07712913** · PHASE3 · RECRUITING · sponsor: **Brainfarma Industria Química e Farmacêutica S/A** · enrollment: 348 (estimated)

## Conditions studied

- Diabetic Neuropathy
- Neuropathic Pain
- Neuralgia, Postherpetic

## Interventions

- **DRUG:** Experimental: Pregabalin XR
- **DRUG:** Comparator: Dorene Tabs
- **DRUG:** Comparator placebo
- **DRUG:** experimental placebo

## Key facts

- **NCT ID:** NCT07712913
- **Lead sponsor:** Brainfarma Industria Química e Farmacêutica S/A
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-18
- **Primary completion:** 2027-06-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 348 (ESTIMATED)
- **Last updated:** 2026-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07712913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07712913, "Extended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07712913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*